News Archive
The discovery opens the possibility that blood vessel growth (angiogenesis) one day may be induced, or stymied, for therapeutic use against heart disease, cancer, and other illnesses, according to Dean Y. Li, M.D., Ph.D., associate professor of internal medicine in the U of U School of Medicine's Division of Cardiology.
The Washington Post examines how the "No Toilet, No Bride" campaign in India is helping to increase access to home toilets in rural India. According to the newspaper, "About 665 million people in India - about half the population - lack access to latrines." Yet, since the campaign launched two years ago, "1.4 million toilets have been built here in the northern state of Haryana, some with government funds, according to the state's health department" - a movement that women's rights activists hail as "a revolution."
Due to their broad antitumor activity that inhibits the function of microtubules, taxanes are common chemotherapeutic agents utilized for the management of multiple cancer types from breast to prostate. Unfortunately, the frequency of their use is equally matched by the rates of expected and well known side effects.
Incyte Corporation (Nasdaq: INCY) today announced that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of achieving phlebotomy independence and reducing spleen size by 35 percent or more.
People with systemic lupus erythematosus are 1.15 times as likely to develop cancer as the general population and more than 2.5 times as likely to develop hematologic malignancies, such as lymphoma and leukemia, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.
› Verified 6 days ago